VetLogic Puzzle 48

ELECTRONIC COPIES OF E-EVP

You can enjoy your E-EVP Current Issue and E-EVP Archive at your NZVA login pages.

1. Go to http://www.nzva.org.nz/ and sign in

2. Click on: > FOR VETERINARY PROFESSIONALS > Branches > New Zealand Equine Veterinary Association [on left] > NZEVA Documents [on left] 3. There you have Current and Archive for E-EVP 4. Or you can View the E-EVP catalogue on SciQuest and download individual pages/articles

VETLOGIC PUZZLE - ANSWER

See page 48 for puzzle

Curly Horse:Wikipedia OWNER HORSE BREED HEIGHT (CM)

Melissa Sim

Curly 170

Grace Reed

Spiti 150

Pip Hendron

Alex Fowler

Kinsky Moyle 160 140

Acutt EV et al. Deep digital flexor tendon lesions in the pastern are associated with the presence of distal tendinopathy. Eq Vet J. June 2021; DOI 10.1111/evj.13470

This was a retrospective descriptive case series involving 88 limbs with deep digital flexor tendon (DDFT) lesions in sport horses. Thirty-four MRI scans of 33 horses and 64 ultrasonographic examinations of 58 horses were analysed. Distal DDFT lesions were found in 75% (95% CI: 66.0-84.0) of total cases of pastern DDF tendinopathy and in 97% (95% CI: 91.6-100.0) of cases with core lesions of the DDFT in the pastern. Core lesions in the pastern were significantly more likely (OR = 20.7, 95% CI: 2.2-191.0; P = 0.008) to be associated with injury in the foot than other types of pastern lesion. As with most retrospective studies, incomplete data retrieval is a problem. But it can be said that when DDFT lesions are found in the pastern, particularly core lesions, further imaging of the tendon within the foot should be considered to help direct more thorough treatment and to help in giving a prognosis for the horse.

Knych HK et al. Pharmacokinetics of transdermal flunixin meglumine and effects on biomarkers of inflammation in horses. J Vet Pharm Therap. June 2021; DOI 10.1111/jvp.12993

Six horses were administered a single transdermal dose of 500 mg of a bovine transdermal flunixin meglumine product. Serum concentrations of flunixin and 5-OH flunixin were above the limit of quantitation at 96 h post-administration in both serum and urine. The mean (range) for C-max, T-max and the terminal half-life were 515.6 (369.7-714.0) ng/ml, 8.67 (8.0 12.0) h, and 22.4 (18.3-42.5) h, respectively. Based on effects on eicosanoid synthesis, flunixin meglumine inhibited COX-1, COX-2 and 15-lipooxygenase activities, with anti-inflammatory effects lasting for 24-72 h.